As Na­tion­al Par­ty Con­gress con­cludes, Chi­na’s FDA seeks to write wide­ly-an­tic­i­pat­ed drug re­forms in­to law

In a bid to move Chi­nese drug in­dus­try reg­u­la­tions clos­er to the US/Eu­ro­pean mod­el, Chi­na’s FDA yes­ter­day pro­posed sig­nif­i­cant changes to the na­tion’s Drug Ad­min­is­tra­tion Act.

The wide­ly ex­pect­ed move comes on the heels of in­struc­tions giv­en two weeks ago by the reign­ing State Coun­cil, Chi­na’s cab­i­net, just pri­or to the 19th Com­mu­nist Par­ty Con­gress meet­ing this past week. It con­firmed Xi Jing­ping as the most pow­er­ful Chi­nese leader since Mao and Deng, en­shrin­ing his per­son­al brand of so­cial­ism “with Chi­nese char­ac­ter­is­tics for a new era” in­to of­fi­cial dog­ma.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER